Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIrR + VDC/IE vs VDC/IE in Newly Diagnosed Metastatic Ewing Sarcoma
NCT06820957Phase 3Terminated
- Sponsor
- Children's Oncology Group
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, regorafenib in Ewing sarcoma, round cell sarcoma, sponsored by Children's Oncology Group. Started Nov 2025; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabregorafenib
03
Conditions
Ewing sarcomaround cell sarcoma
Beyond the preview
Go deeper on NCT06820957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820957.